My guess is that Malone might getting more expensive because of the accounting complexities (derivatives, Bio Art consolidation and structure) and the restatements. There aren't a lot of options. I am betting we may see another 10KA before we see the Q's. Switching firms buys them a few more months in filing.
News 
Market Data 
Discover 
